motixafortide 62 MG Injection

RxCUI: 2664901
RxNorm name: motixafortide 62 MG Injection
Display name: motixafortide 62 MG Injection
Full name: motixafortide 62 MG Injection
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:39:25

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
APHEXDA	MOTIXAFORTIDE	Gamida Cell Inc.	e704b2db-f119-40ba-9346-9229e3281c9e	2026-06-04	Warnings, Adverse reactions	Exact identifier rxcui: 2664901
Aphexda	MOTIXAFORTIDE	BioLineRx USA Inc	f7cdc584-ebf0-a68e-e053-6294a90a9ea9	2024-10-10	Warnings, Adverse reactions	Exact identifier rxcui: 2664901

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
e704b2db-f119-40ba-9346-9229e3281c9e	motixafortide 62 MG Injection	SCD	4	These highlights do not include all the information needed to use APHEXDA safely and effectively. See full prescribing information for APHEXDA. APHEXDA ® (motixafortide) for injection, for subcutaneous use Initial U.S. Approval: 2023	20251028
e704b2db-f119-40ba-9346-9229e3281c9e	motixafortide 62 MG Injection	PSN	4	These highlights do not include all the information needed to use APHEXDA safely and effectively. See full prescribing information for APHEXDA. APHEXDA ® (motixafortide) for injection, for subcutaneous use Initial U.S. Approval: 2023	20251028
e704b2db-f119-40ba-9346-9229e3281c9e	motixafortide 62 MG (as motixafortide acetate) Injection	SY	4	These highlights do not include all the information needed to use APHEXDA safely and effectively. See full prescribing information for APHEXDA. APHEXDA ® (motixafortide) for injection, for subcutaneous use Initial U.S. Approval: 2023	20251028
f7cdc584-ebf0-a68e-e053-6294a90a9ea9	motixafortide 62 MG Injection	PSN	2	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use APHEXDA safely and effectively. See full prescribing information for APHEXDA. APHEXDA TM (motixafortide) for injection, for subcutaneous use. Initial U.S. Approval: 2023	20241010
f7cdc584-ebf0-a68e-e053-6294a90a9ea9	motixafortide 62 MG Injection	SCD	2	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use APHEXDA safely and effectively. See full prescribing information for APHEXDA. APHEXDA TM (motixafortide) for injection, for subcutaneous use. Initial U.S. Approval: 2023	20241010
f7cdc584-ebf0-a68e-e053-6294a90a9ea9	motixafortide 62 MG (as motixafortide acetate) Injection	SY	2	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use APHEXDA safely and effectively. See full prescribing information for APHEXDA. APHEXDA TM (motixafortide) for injection, for subcutaneous use. Initial U.S. Approval: 2023	20241010